Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19 ...

Recent discussions on X about Moderna, Inc. (MRNA) have been buzzing with excitement following the company's announcement of positive late-stage trial results for its experimental mRNA-based ...

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial.